表紙
市場調查報告書
商品編碼
960378

偏頭痛治療的全球市場(按給藥途徑,治療類別,地區分):考慮和預測,新冠狀病毒感染的潛在影響(COVID-19)(2020-2024)

Global Migraine Drugs Market (by Mode of Administration, Treatment Class & Regions): Insights and Forecast with Potential Impact of COVID-19 (2020-2024)

出版日期: | 出版商: Koncept Analytics | 英文 107 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

到2020年至2024年,偏頭痛藥物的全球市場預計將以3.7%的複合年增長率增長,到2024年將達到51億美元。女性人口增加,煙草消費增加和壓力增加是市場的主要推動力,但最近由於新的冠狀病毒感染(COVID-19)爆發而受到限制。隨著壓力水平的進一步提高和偏頭痛患者人數的增加,市場有望進一步擴大。另外,已經在新藥的研發(R&D)上投入了大量資金,並且有望在未來的臨床試驗中取得重大進展。按照治療類別,有望在不久之後針對類胰蛋白□難治或有心血管疾病風險的患者推出同類藥物中的第一種新藥。

該報告分析了偏頭痛治療的全球市場,並提供了總體市場規模前景(過去/未來5年),管理途徑/治療類別以及地區/國家/地區。我們正在調查詳細的趨勢,主要的市場推廣/抑制因素,公司之間的競爭狀況/性能比較,主要公司的概況以及COVID-19感染傳播的影響。

目錄

第1章概述

  • 頭疼
  • 偏頭痛的類型
  • 偏頭痛階段
  • 診斷程序
  • 如何治療偏頭痛
  • CGRP(降鈣素基因相關□)-偏頭痛治療的新時代

第2章COVID-19的影響

  • 壓力增加
  • 政府醫療費用增加
  • 飲酒量增加
  • 過度使用手部消毒劑的影響

第3章世界市場分析

  • 偏頭痛治療藥物的市場規模(價值基礎)
  • 偏頭痛治療藥物的市場規模,預測值(價值基準)
  • 偏頭痛治療藥物的市場規模:按給藥途徑(RoA)
    • 口服藥物
    • 注射
  • 偏頭痛治療藥物的市場規模:按治療類別
    • 急性治療藥物(破壞性藥物)
    • 預防藥物
  • 偏頭痛治療藥物的市場規模:按地區

第4章區域市場

  • 北美
    • 市場規模(基於價值)
    • 市場規模,預測值(金額基準)
    • 市場規模:按地區
    • 美國:市場規模(基於價值)
    • 美國:預測(基於價值)
  • 歐洲
  • 亞太地區
  • 其他國家(行)

第5章市場動態

  • 生長促進劑
    • 女性人口增加
    • 煙草消費量增加
    • 藥品的研發(R&D)成本增加
    • 加快經濟增長
    • 醫療費用增加
    • 壓力增加
    • 未滿足的醫療需求
    • 偏頭痛的患病率
  • 主要趨勢和動向
    • 製藥和生物技術行業的研發增加
    • CGRP目標藥物:目前正在開發的管道產品
    • 復發性偏頭痛的品牌急性療法
    • 對偏頭痛及其治療的興趣日益濃厚
    • 進一步治療偏頭痛
  • 挑戰
    • 藥物的副作用
    • 缺乏正確的診斷
    • 對替代療法的偏好增加
    • 監管問題
    • 大筆相關費用

第6章競爭情況

  • 世界市場
    • 市場收入比較:主要公司之間
    • 研發費用比較:主要公司之間
    • 股票市值比較:大公司之間
  • 美國市場
    • 偏頭痛的美國CGRP藥物市場:滲透率預測(針對大公司)
    • 美國CGRP慢性偏頭痛藥物市場:市場份額預測(針對大型公司)

第7章公司簡介

  • Novartis AG
  • Merck and Co.
  • Amgen AG
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Lundbeck
目錄

The global migraine market is expected to reach US$5.10 billion in 2024, growing at a CAGR of 3.7%, for the duration spanning 2020-2024. The factors such as growing female population, increasing cigarette consumption, increasing pharmaceutical R&D expenditures, accelerating economic growth, increasing healthcare spending, increasing stress levels, unmet medical needs and prevalence of migraine at high rates would drive the growth of the market. However, the market growth would be challenged by adverse effect of drugs, lack of proper diagnosis, increased preferences for alternative options, regulatory challenges and high cost associated. A few notable trends include, growth in pharmaceutical & biotech merger & acquisition, progressing CGRP targeting drug pipeline, branded acute treatment for episodic migraine, growing awareness regarding migraine and its therapeutics and development of additional migraine therapeutics.

The global migraine market holds a lucrative growth opportunity for the coming future due to the high prevalence rate of migraine among people. Migraine market is expected to witness the advent of first-in-class novel migraine therapeutics, especially meant for patients who are unresponsive to triptans or ones at risk of cardiovascular disorders. A considerable amount of funds are being invested in the research and development of new migraine drugs, in order to make such therapeutics available in market. A number of drugs are under late stage clinical process and some therapeutics are registered for the FDA approval. Launches of new migraines drugs would thereby help the migraine market to grow globally in coming years.

The fastest growing regional market is North America, due to the presence of well established healthcare infrastructure as well as major pharmaceutical players. Increased retail sales of triptans and ergot alkaloids, demanded by the people with acute migraine conditions for the abortive purpose, helped the market to grow at a considerable pace in the region. Europe and Asia Pacific also secured considerable shares in the migraine market, owing to the high prevalence rate of migraine, along with the increased programmes of collaboration and partnership in the pharmaceutical sector. Further, the sudden outbreak of COVID-19, would trigger the stress levels among people, due to the implementation of the lockdown measures, which would elevate the risk of migraine among them and thereby is expected to accelerate the growth of the global migraine market in coming years.

Scope of the report:

  • The report provides a comprehensive analysis of the global monoclonal antibodies market.
  • The major regional markets (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Novartis AG, Merck & Co., AbbVie Inc., Bristol-Myer Squibb and Amgen AG) are also presented in detail.

Key Target Audience:

  • Monoclonal Antibodies Manufacturers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals and Research Institutes)
  • Investment Banks
  • Healthcare and Medical Consultants
  • Government Bodies & Regulating Authorities

Table of Contents

1. Overview

  • 1.1 Migraine
  • 1.2 Types of Migraine
  • 1.3 Stages of Migraine
  • 1.4 Diagnosis Procedures
  • 1.5 Migraine Treatment
  • 1.6 CGRP - A New Era of Migraine Treatment

2. Impact of COVID-19

  • 2.1 Rise in Stress Level
  • 2.2 Growth in Government Spending on Healthcare
  • 2.3 Increase in Alcohol Consumption
  • 2.4 Impact of Excessive Use of Hand Sanitizers

3. Global Market Analysis

  • 3.1 Global Migraine Drugs Market by Value
  • 3.2 Global Migraine Drugs Market Forecast by Value
  • 3.3 Global Migraine Drugs Market by Mode of Administration
    • 3.3.1 Global Oral Migraine Drugs Market by Value
    • 3.3.2 Global Oral Migraine Drugs Market Forecast by Value
    • 3.3.3 Global Injectable Migraine Drugs Market by Value
    • 3.3.4 Global Injectable Migraine Drugs Market Forecast by Value
  • 3.4 Global Migraine Drugs Market by Treatment Class
    • 3.4.1 Global Abortive Migraine Drugs Market by Value
    • 3.4.2 Global Abortive Migraine Drugs Market Forecast by Value
    • 3.4.3 Global Preventative Migraine Drugs Market by Value
    • 3.4.4 Global Preventative Migraine Drugs Market Forecast by Value
  • 3.5 Global Migraine Drugs Market by Regions

4. Regional Market

  • 4.1 North America
    • 4.1.1 North America Migraine Drugs Market by Value
    • 4.1.2 North America Migraine Drugs Market Forecast by Value
    • 4.1.3 North America Migraine Drugs Market by Region
    • 4.1.4 The U.S. Migraine Drugs Market by Value
    • 4.1.5 The U.S. Migraine Drugs Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Migraine Drugs Market by Value
    • 4.2.2 Europe Migraine Drugs Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Migraine Drugs Market by Value
    • 4.3.2 Asia Pacific Migraine Drugs Market Forecast by Value
  • 4.4 ROW
    • 4.4.1 ROW Migraine Drugs Market by Value
    • 4.4.2 ROW Migraine Drugs Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Growing Female Population
    • 5.1.2 Increasing Cigarette Consumption
    • 5.1.3 Increasing Pharmaceutical R&D Spending
    • 5.1.4 Accelerating Economic Growth
    • 5.1.5 Increasing Healthcare Spending
    • 5.1.6 Increasing Stress Levels
    • 5.1.7 Unmet Medical Needs
    • 5.1.8 Prevalence of Migraine at High Rate
  • 5.2 Key Trends and Developments
    • 5.2.1 Growth in Pharmaceutical and Biotech Merger & Acquisition
    • 5.2.2 Progressing CGRP - Targeting Drug Pipeline
    • 5.2.3 Branded Acute Treatment for Episodic Migraine
    • 5.2.4 Growing Awareness about Migraine and its Treatment
    • 5.2.5 Development of Additional Migraine Therapeutics
  • 5.3 Challenges
    • 5.3.1 Adverse Effects of Drugs
    • 5.3.2 Lack of Proper Diagnosis
    • 5.3.3 Increased Preference for Alternative Therapies
    • 5.3.4 Regulatory Challenges
    • 5.3.5 High Cost Associated

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Key Players - Revenue Comparison
    • 6.1.2 Key Players - R&D Expenditure Comparison
    • 6.1.3 Key Players - Market Capitalization Comparison
  • 6.2 The U.S. Market
    • 6.2.1 Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast
    • 6.2.2 Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast

7. Company Profiles

  • 7.1 Novartis AG
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Merck and Co.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Amgen AG
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Eli Lilly and Company
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Teva Pharmaceuticals
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Lundbeck
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Figures

  • Migraine
  • Diagnosis Procedures
  • Global Government Share on Health Spending (2019-2024)
  • Global Alcoholic Beverage Consumption (2017-2021)
  • Global Migraine Drugs Market by Value (2015-2019)
  • Global Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Mode of Administration (2019)
  • Global Oral Migraine Drugs Market by Value (2015-2019)
  • Global Oral Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Injectable Migraine Drugs Market by Value (2015-2019)
  • Global Injectable Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Treatment Class (2019)
  • Global Abortive Migraine Drugs Market by Value (2015-2019)
  • Global Abortive Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Preventative Migraine Drugs Market by Value (2015-2019)
  • Global Preventative Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Regions (2019)
  • North America Migraine Drugs Market by Value (2015-2019)
  • North America Migraine Drugs Market Forecast by Value (2020-2024)
  • North America Migraine Drugs Market by Region (2019)
  • The U.S. Migraine Drugs Market by Value (2015-2019)
  • The U.S. Migraine Drugs Market Forecast by Value (2020-2024)
  • Europe Migraine Drugs Market by Value (2015-2019)
  • Europe Migraine Drugs Market Forecast by Value (2020-2024)
  • Asia Pacific Migraine Drugs Market by Value (2015-2019)
  • Asia Pacific Migraine Drugs Market Forecast by Value (2020-2024)
  • ROW Migraine Drugs Market by Value (2015-2019)
  • ROW Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Female Population (2015-2019)
  • Global Cigarette Consumption (2014-2018)
  • Global Pharmaceutical R&D Spending (2015-2019)
  • Global GDP Per Capita (2014-2018)
  • Global Healthcare Spending Per Capita (2014-2018)
  • Global Pharmaceutical and Biotech M&A (2015-2019)
  • Novartis AG Net Sales and Net Income (2015-2019)
  • Novartis AG Net Sales by Segments (2019)
  • Novartis AG Net Sales by Regions (2019)
  • Merck and Co. Sales and Net Income (2015-2019)
  • Merck and Co. Sales by Segments (2019)
  • Merck and Co. Sales by Regions (2019)
  • Amgen AG Total Revenue and Net Income (2015-2019)
  • Amgen AG Total Revenue by Divisions (2019)
  • Amgen AG Total Revenue by Regions (2019)
  • Eli Lilly and Company Revenue and Net Income (2015-2019)
  • Eli Lilly and Company Revenue by Divisions (2019)
  • Eli Lilly and Company Revenue by Regions (2019)
  • Teva Pharmaceuticals Revenue and Net Loss (Income) (2015-2019)
  • Teva Pharmaceuticals Revenue by Regions (2019)
  • Lundbeck Revenue and Profit (2015-2019)
  • Lundbeck Revenue by Regions (2019)

List of Tables

  • Difference Between Episodic and Chronic Migraine
  • Stages of Migraine
  • Global Share of Adults Experiencing Stress During COVID-19 (2020)
  • Progressing CGRP - Targeting Drug Pipeline
  • Branded Acute Treatment for Episodic Migraine
  • Key Players - Revenue Comparison (2019)
  • Key Players - R&D Expenditure Comparison
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast (2019-2023)
  • Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast (2019-2023)